Table 2.
Regression analysis showing univariate and multivariate associations between discontinuation of subcutaneous vedolizumab and covariates at switch
| Univariate | |||
|---|---|---|---|
| HR | 95% CI | P-value | |
| Age at switch | 0.99 | 0.98–1.02 | .984 |
| Diagnosis | 1.5 | 0.70–3.18 | .303 |
| Harvey Bradshaw Index, (0–16) | 1.12 | 1.01–1.26 | .039 |
| Partial Mayo Score, (0–3) | 1.92 | 1.12–3.29 | .017 |
| Fecal Calprotectin ≥ 250 mg/kg | 2.76 | 1.08–7.02 | .033 |
| C-reactive protein ≥ 5.0 mg/L | 1.23 | 0.50–3.04 | .649 |
| Serum vedolizumab | 1.02 | 0.96–1.09 | .521 |
| Subcutaneous VDZ dose (mg/day) | 1.20 | 1.05–1.37 | .009 |
| Clinical remissiona | 0.34 | 0.16–0.73 | .006 |
| Biochemical remissionb | 0.43 | 0.17–1.06 | .067 |
| Combined remissionc | 0.39 | 0.14–0.97 | .043 |
| Preference No preference/subcutaneous (reference) |
1 | - | - |
| Intravenous | 2.78 | 1.31–5.90 | .008 |
| Multivariate | |||
| Clinical remission | 0.27 | 0.09–0.81 | .019 |
| Fecal Calprotectin ≥ 250 mg/kg | 2.97 | 0.72–12.23 | .131 |
| Subcutaneous VDZ dose (mg/day) | 0.96 | 0.76–1.23 | .772 |
| Intravenous preference | 3.84 | 1.46–10.06 | .006 |
Italic numbers indicate statistical significance.
aPartial Mayo Score without physician's assessment ≤ 1 for Ulcerative colitis and Harvey Bradshaw Index ≤ 4 for Crohn’s disease.
bC-reactive protein < 5 mg/L and Fecal Calprotectin <250 mg/kg.
cClinical and biochemical remission.